7 results
Autoantibodies in Rheumatology
 • Lupus (SLE): ANA (anti-nuclear antibody), dsDNA (double-stranded DNA), Anti-Smith, Anti-Ro (SSA) and
Lupus (SLE): ... Myositis: Anti-JO-1, ... • Scleroderma (Systemic ... RNA Polymerase Ill ... #associations #table
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
-1 and IL-6, leading ... lupus erythematosus ... lupus erythematosus ... Treatment: • Corticosteroids ... #Rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
to 1:1 F:M • Clinical ... Prognosis: Usually mild ... months to years) Systemic ... sle #comparison #table ... #rheumatology #
Antinuclear antibodies and Systemic lupus
Anti-dsDNA	60-80%	Association with disease activity (when with Farr assay) and lupus nephritis. Can
-15% If SLE is clinically ... SLE-SSc-AlM overlap syndromes ... Anti-PCNA 1-5% ... #diagnosis #rheumatology ... #table #ANA
SLE (Systemic Lupus Erythematosus)

Suspect:
Clinical evidence of (fatigue, rash, photosensitivity, inflammatory arthritis, weight loss, and fever) and
SLE (Systemic Lupus ... ) Suspect: Clinical ... pneumonitis • ... • ANA titers > 1: ... Ro/La, anti-Jo-1,
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
Epidemiology: • F > M: 9:1 ... salivary ducts Clinical ... • Interstitial Pneumonitis ... Adenocarcinoma Treatment ... #Rheumatology #
Hemophagocytic Lymphohistiocytosis (HLH)

High mortality without prompt recognition and management. HLH is a critical diagnostic consideration in
HLH is a critical ... dysfunction. 1. ... of the immune system ... Clinical Presentation ... Diagnosis #Management #Hematology